OPK NASDAQ
OPKO Health, Inc.
1W: -4.9%
1M: -7.7%
3M: +4.0%
YTD: +22.8%
1Y: +0.7%
3Y: +0.0%
5Y: -58.4%
$1.56
-0.01 (-0.64%)
Weekly Expected Move ±5.4%
$1
$1
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
24 relationships20
As Filer
counterparties named
4
As Counterparty
mentioned by others
5
Rel. Types
2021-06-21
Earliest Filing
2026-02-04
Latest Filing
acquirer: 7
target: 7
partner: 4
investor: 1
licensee: 1
Counterparties (Filed by OPK)
20 relationshipsCompanies named in OPK's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Labcorp | LH | acquirer | Acquiring select oncology and clinical testing assets from BioReference Health | 2025-03-11 | View |
| OPKO Health | OPK | target | Selling select oncology assets through its subsidiary BioReference Health | 2025-03-11 | View |
| BioReference Health | — | target | Wholly owned subsidiary of OPKO Health whose assets are being acquired | 2025-03-11 | View |
| Labcorp | LH | acquirer | Acquired select assets of BioReference Health's diagnostics business from OPKO Health | 2024-09-16 | View |
| OPKO Health | OPK | target | Sold select assets of its wholly owned subsidiary BioReference Health to Labcorp | 2024-09-16 | View |
| BioReference Health | — | target | Wholly owned subsidiary of OPKO Health whose diagnostics assets were acquired by Labcorp | 2024-09-16 | View |
| OPKO Health | OPK | acquirer | Entered into a $250 million note purchase agreement with HealthCare Royalty. | 2024-07-17 | View |
| Ernst & Young LLP | — | investor | Independent registered public accounting firm that certified financial statements. | 2024-01-09 | View |
| Merck Sharp & Dohme LLC | MRK | partner | Entered into a License and Research Collaboration Agreement with ModeX for vaccine development | 2023-03-08 | View |
| Sanofi | SNYNF | partner | ModeX obtained certain rights from Sanofi under a prior in-license agreement | 2023-03-08 | View |
| ModeX Therapeutics, Inc. | — | target | Target company acquired by OPKO Health, Inc. via merger | 2022-05-13 | View |
| Orca Acquisition Sub, Inc. | — | acquirer | Wholly owned subsidiary of OPKO Health, Inc. used to acquire ModeX | 2022-05-13 | View |
| Sema4 Holdings Corp. | — | acquirer | Acquired GeneDx in a merger transaction for $150M cash and 80M shares of common stock. | 2022-05-04 | View |
| Sema4 Holdings Corp. | — | acquirer | Acquired OPKO Health, Inc. and its subsidiary GeneDx Inc. in a merger transaction. | 2022-01-18 | View |
| GeneDx Inc. | WGSWW | target | Wholly owned subsidiary of OPKO Health, Inc. that was merged into Sema4 Holdings Corp. | 2022-01-18 | View |
| CAMP4 Therapeutics Corporation | CAMP | licensee | OPKO granted an exclusive license for AntagoNAT technology to CAMP4 in exchange for upfront payment, preferred stock, an | 2021-07-12 | View |
| EirGen Pharma Limited | — | target | Seller of sterile fill finish facility assets to Horizon Therapeutics Ireland DAC | 2021-06-23 | View |
| Horizon Therapeutics Ireland DAC | — | acquirer | Buyer of sterile fill finish facility assets from EirGen Pharma Limited | 2021-06-23 | View |
| EirGen Pharma Limited | — | partner | Irish subsidiary of OPKO Health, Inc. that entered into a Development and License Agreement with Nicoya. | 2021-06-21 | View |
| NICOYA Macau Limited | — | partner | Macau corporation and affiliate of NICOYA Therapeutics that received exclusive rights to develop and commercialize exten | 2021-06-21 | View |
Mentioned As Counterparty
4 mentionsOther companies that named OPK in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| ENTX Entera Bio Ltd. | partner | Delaware corporation entering collaboration and license agreement | 2026-02-04 | View |
| ENTX Entera Bio Ltd. | partner | Collaborator and potential commercialization partner for oral products | 2025-03-17 | View |
| WGSWW Sema4 Holdings Corp. | target | Parent company of GeneDx, Inc. and acquirer of Sema4 Holdings Corp. | 2022-05-02 | View |
| WGSWW Sema4 Holdings Corp. | target | Parent company of GeneDx, Inc. and counterparty in the merger agreement. | 2022-01-18 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-02 | Other Events | View | |
| 2026-08-14 | Material Agreement; Financial Obligation; Exhibits | Agreement | View |
| 2026-07-27 | Earnings Release; Exhibits | View | |
| 2026-06-18 | Shareholder Vote | View | |
| 2026-04-28 | Earnings Release; Exhibits | View | |
| 2026-02-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-29 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-09-15 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-07-31 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-05-29 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-04-30 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-23 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-04-01 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities | Agreement | View |
| 2025-03-28 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities | Agreement | View |
| 2025-03-11 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2025-02-27 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-15 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2024-11-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-09-16 | Termination of Material Definitive Agreement; Completion of Acquisition or Disposition of Assets; Re | Acquisition | View |
| 2024-08-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR